Milestone reached in search of vaccine against respiratory syncytial virus
A new study has showed how a bioengineered RSV protein vaccine can induce a protective immune response in animal models.
List view / Grid view
A new study has showed how a bioengineered RSV protein vaccine can induce a protective immune response in animal models.
Eli Lilly scientists report that they have designed, qualified and enabled a high-throughput plasmid purification and quantification workstation.
Listen to this podcast to discover why mAbs are key in the fight against SARS-CoV-2 and how the pandemic has shaped their development pipeline.
Researchers at UC Davis Health have engineered an antibody that interferes with a critical cell mechanism to reduce transmission of the virus that causes COVID-19 in lab tests.
Scientists at Georgia State University have developed an intranasal influenza vaccine using a new combination of nanoparticles for improved defence against flu strains.
Janssen's monoclonal antibody CR9114, for the potential treatment of influenza, has been exclusively licensed by Leyden Labs for development and commercialisation.
Research has shown that memory T cells formed following SARS-CoV-2 infection or mRNA vaccination respond to the Omicron variant.
Sino Biological has announced that its new location in Houston, Texas, is now open, expanding the company geographically.
To support disease research, Sino Biological has deposited reagents for the Omicron variant to BEI Resources.
News from the Pasteur Institute in France reports on how multi organisational efforts of numerous research institutes enabled the scientific community to gain key insight into the Omicron variant, facilitating a rapid life-saving response.
A study has revealed four classes of antibodies that can neutralise Omicron by targeting one of four areas of the spike protein present in SARS-CoV-2 variants.
Researchers have found a small subset of antibodies that target a site at the base of the influenza virus hemagglutinin protein.
Scientists have developed a metal-organic framework that, when attached to antibodies, improved their targeted delivery in in vitro studies.
Sino Biological has developed recombinant Omicron Spike RBD protein and antibody reacting with Omicron to support the study of Omicron variant.
In this article, Dr Shishir Chundawat and Aron Gyorgypal from Rutgers University, US, explain how they developed a new process analytical technology (PAT) system for the automated monitoring of antibody N-glycosylation.